Trial site
The Affiliated Hospital of Hangzhou Normal University
- 14running trials
- 5closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Conditions
- Fatty liver disease (MASLD/MASH)5 trials
- Coronary artery disease3 trials
- Liver cirrhosis3 trials
- Bronchiectasis2 trials
- High blood pressure2 trials
- Irritable bowel syndrome2 trials
- Alzheimer disease1 trial
- Parkinson disease1 trial
- Stroke1 trial
- Phase
- Phase 26 trials
- Phase 34 trials
- Phase 43 trials
- Status
- Active, not recruiting6 trials
- Recruiting5 trials
- Completed3 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Boehringer Ingelheim4 trials
- The Affiliated Hospital of Hangzhou Normal University3 trials
- Second Affiliated Hospital, Zhejiang University, School of Medicine2 trials
- Zhejiang Doer Biologics Co., Ltd.2 trials
- Cascade Pharmaceuticals, Inc1 trial
- and 7 more
Running trials
Recruiting
Not yet recruiting
Active, not recruiting
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
Active, not recruiting
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
Recruiting
Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Active, not recruiting
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Fatty liver disease (MASLD/MASH)2 recruiting
- Irritable bowel syndrome2 recruiting
- Bronchiectasis1 recruiting
- Coronary artery disease1 recruiting
- Liver cirrhosis1 recruiting
- Parkinson disease1 recruiting
Closed trials
Completed
Completed
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
Terminated
Terminated
Completed
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Site data: ClinicalTrials.govUpdated 19 Nov 2026